CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets.

Human regulatory T cells (Treg) suppress other immune cells. Their dysfunction contributes to the pathophysiology of autoimmune diseases, including type 1 diabetes (T1D). Infusion of Tregs is being clinically evaluated as a novel way to prevent or treat T1D. Genetic modification of Tregs, most notably through the introduction of a chimeric antigen receptor (CAR) targeting Tregs to pancreatic islets, may improve their efficacy. We evaluated CAR targeting of human Tregs to monocytes, a human β cell line and human islet β cells

Informations de copyright

Copyright © 2024 Wu, Chen, Whitener, MacDougall, Coykendall, Yan, Kim, Harper, Pathak, Iliopoulou, Hestor, Saunders, Spears, Sévigny, Maahs, Basina, Sharp, Gloyn, Powers, Kim, Jensen and Meyer.

Déclaration de conflit d'intérêts

EM: Sponsored research funding and scientific advisory Orca Biosciences, Scientific Advisory and equity holder, Tract Therapeutics, Indee Labs, Jura Biosciences, Saffron Therapeutics. Scientific Advisory CTI, Kyverna. KJ is an investor equity holder and Scientific Advisor Consultant to Deka Biosciences. MM is scientific advisory board member, consultant, and equity holder in Syntax Bio. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.